CAR T-cell Availability for Multiple Myeloma Improving but Still Limited

Area of Science:

• Oncology
• Cellular Therapy
• Biomanufacturing

Background:

• CAR T-cell therapy is a promising treatment for multiple myeloma.
• Patient access to CAR T-cell therapy is limited by manufacturing capacity.
• A 2022 survey highlighted significant treatment gaps.

Purpose of the Study:

• To assess the current accessibility of CAR T-cell therapy for multiple myeloma patients.
• To identify key factors limiting CAR T-cell therapy production and delivery.
• To project future demand based on potential treatment expansion.

Main Methods:

• Analysis of a 2022 patient survey data.
• Identification of manufacturing bottlenecks, including viral vector supply.
• Evaluation of potential impacts of new manufacturing and testing approaches.

Main Results:

• Only approximately 25% of surveyed multiple myeloma patients received CAR T-cell therapy.
• Manufacturing bottlenecks, specifically viral vector shortages, were identified as primary limitations.
• Potential for increased demand if CAR T-cell therapy is approved for earlier treatment stages.

Conclusions:

• Current CAR T-cell therapy manufacturing capacity is insufficient to meet patient demand.
• Innovations in cell manufacturing and testing are crucial for improving patient access.
• Anticipating and addressing future demand is essential for widespread CAR T-cell therapy adoption.